Akero Therapeutics, Inc. (NASDAQ:AKRO) Director Acquires $2,177,500.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) Director G. Walmsley Graham bought 50,000 shares of the business’s stock in a transaction on Thursday, March 27th. The stock was bought at an average price of $43.55 per share, with a total value of $2,177,500.00. Following the purchase, the director now owns 1,200,000 shares in the company, valued at $52,260,000. This trade represents a 4.35 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

G. Walmsley Graham also recently made the following trade(s):

• On Tuesday, March 25th, G. Walmsley Graham purchased 91,309 shares of Akero Therapeutics stock. The stock was purchased at an average cost of $44.75 per share, for a total transaction of $4,086,077.75.
• On Thursday, January 30th, G. Walmsley Graham acquired 200,000 shares of Akero Therapeutics stock. The shares were purchased at an average cost of $48.00 per share, with a total value of $9,600,000.00.

Akero Therapeutics Trading Up 0.7 %

Shares of AKRO traded up $0.29 during mid-day trading on Thursday, reaching $43.58. The company’s stock had a trading volume of 441,531 shares, compared to its average volume of 805,011. Akero Therapeutics, Inc. has a 52 week low of $17.86 and a 52 week high of $58.40. The stock has a market cap of $3.47 billion, a PE ratio of -11.62 and a beta of -0.19. The company’s fifty day moving average price is $45.66 and its two-hundred day moving average price is $34.90. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.01). On average, analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on AKRO. Canaccord Genuity Group boosted their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. UBS Group lifted their price objective on Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Bank of America upgraded Akero Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. Citigroup raised their target price on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $76.29.

Institutional Investors Weigh In On Akero Therapeutics

Several institutional investors have recently bought and sold shares of AKRO. abrdn plc lifted its position in Akero Therapeutics by 118.7% in the fourth quarter. abrdn plc now owns 269,782 shares of the company’s stock valued at $7,505,000 after purchasing an additional 146,424 shares during the last quarter. FMR LLC increased its stake in shares of Akero Therapeutics by 732.1% in the third quarter. FMR LLC now owns 30,337 shares of the company’s stock worth $870,000 after buying an additional 26,691 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Akero Therapeutics by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company’s stock worth $15,042,000 after buying an additional 8,096 shares during the period. Proficio Capital Partners LLC bought a new stake in Akero Therapeutics during the 4th quarter valued at $320,000. Finally, SG Americas Securities LLC boosted its position in Akero Therapeutics by 4,022.1% during the 4th quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock valued at $16,636,000 after buying an additional 583,486 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.